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upper GI bleeding, 11 for lower, and 16 for intra-procedural bleeding/prophylaxis 
therapy. Initial hemostasis was achieved in 66 cases (98.5%), with 6 cases (9.5%) 
of early rebleeding and 9 cases (14.3%) of delayed rebleeding. No serious adverse 
events were noted. Remnants of TC-325 powder were not identified even when 
second-look endoscopy was performed within 24 hours. ConClusions: To our 
knowledge this is the largest retrospective observational study looking at TC-325 
in variety of pathologies in the upper and lower GI tract. Initial hemostasis was 
excellent; subsequent rebleeding rates varied according to etiology and appear-
ance of lesions. The residency time of the powder was short-lived with complete 
elimination from the GI tract within 24 hours of use based on a few observations. 
No serious adverse events were noted.
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objeCtives: This study aims to determine the effectiveness of chewing a gum 
on salivation, passing out of flatus, bowel movement and gastric motility among 
Filipino elderly. Methods: The study utilized a quasi-experimental design. A non-
probability purposive sampling was utilized in subjects (n= 20) selection with inclu-
sion criteria being: (a) Filipino elderly aged 60 years old and above (b) able to chew (c) 
not taking any laxatives (d) willing to participate. Purposive sampling method was 
used, divided the respondents into: experimental and control group. Experimental 
group consisted of 10 subjects while control group 10 subjects. Study was conducted 
consecutively three days. Lunch was served with a 10 minutes post-lunch rest. The 
experimental group was given three pellets of chewing gum followed by a rest period 
of ten minutes-time allotted for masseter muscle to relax. Respondent’s physiologic 
changes such as salivation, passing of flatus and bowel movement were monitored, 
data documented. Second phase of gum chewing performed and same process fol-
lowed. Results: Data revealed that outcome of each elderly in relation to the three 
physiological processes varies. Salivation yielded a p-value of 0.045 (p value < 0.05), 
passage of flatus obtained a p-value of 0.001 (p value < 0.05) and bowel movement 
has p-value of 0.0429 (p value < 0.05), which means there is significant difference 
between the chewing gum and the non-chewing gum in terms of these three vari-
ables. ConClusions: Chewing a gum is an effective intervention in enhancing 
gastric motility among elderly.
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objeCtives: Besides the great concern about safe choices during pregnancy in 
inflammatory bowel disease (IBD) patients, several current trials have indicated 
the harmful effect of flare-up periods in pregnant women with IBD on their new-
borns more than continuing maintenance therapy. Therefore, an effective medical 
treatment is of great importance and necessary during pregnancy. Our aim was 
to perform a meta-analysis on the outcomes of thiopurines use and a systematic 
review of anti-TNF drugs use during pregnancy in women with IBD. Methods: 
All cohort studies in which evaluated the pregnancy outcomes of thiopurines and/
or anti-TNF drugs during pregnancy in IBD women up to 2013 July were collected 
and analyzed. In the meta-analysis a total of 312 pregnant women with IBD that 
used thiopurines were compared to 1149 controls to evaluate the drug effect on 
different pregnancy outcomes including prematurity, low birth weight, congenital 
abnormalities, spontaneous abortion and neonatal adverse outcomes. Results: 
Results of statistical analysis demonstrated that, congenital abnormalities were 
increased significantly in thiopurine exposed group in comparison to control group 
that did not receive any mediciness for IBD treatment. The summary OR was 2.95 
with 95% CI = 1.03 to 8.43 (P = 0.04). We have observed no significant differences in 
occurrence of other adverse pregnancy outcomes between compared groups. The 
results of cohorts that evaluated the safety of anti-TNF drugs during pregnancy 
demonstrated no increase in occurrence of adverse pregnancy outcomes in com-
pare to controls except for the significant decrease in gestational age of newborns 
of drug exposed mothers in one trial. ConClusions: In conclusion due to the 
limited existing evidence, benefit-risk ratio should be considered in prescribing or 
continuing medicinal therapy during pregnancy.
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objeCtives: To assess the health effectiveness, cost and cost-effectiveness of 
different Viral Load Test (VLT) in Response Guided Treatment of peg-interferon 
alpha-2a plus ribavirin for chronic hepatitis C. Methods: Decision tree of COBAS 
test and domestic test were developed on the basis of Response Guided Treatment 
(RGT), and short term test efficacy, treatment response and long term outcomes 
of SVR or Non SVR were derived from literatures. Results: The long term result 
of COBAS test plus standard treatment was 30.57LYs and 19.11QALYs, while the 
total cost was 70,287.91CNY. 30.34Lys and 18.89QALYs were acquired by domestic 
test while the total cost was 74,151.83CNY. Relatively, 0.23 QALYs (0.23LYs) were 
prolonged and 3,864CNY was saved per CHC patient via COBAS test compared with 
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objeCtives: Sulphonylureas available in Malaysia include glibenclamide, gliclazide, 
glimepiride and glipizide providing varying degree of benefits and risks. In this study 
we review and compare overall utility values of sulphonylureas using medicines 
scoring system (MedSS). Methods: MedSS, a previously developed scoring frame-
work based on multicriteria decision analysis (MCDA) that systematizes evaluation 
of drug attributes was used. An expert panel of 3 endocrinologists, 1 family physi-
cian and 5 pharmacists were formed. A group of medicine reviewers assisted in 
evidences search and reviews. Through expert panel discussions, drug attributes 
were identified and weighted. Based on evidences, attribute scores were allocated 
and added up to provide total utility score (TUS). Cost savings was calculated based 
on 25% reduction in utilization of drug with the lowest TUS. Results: Attributes 
identified and selected for analysis were efficacy (clinical efficacy, clinical end-
points), safety (interactions, side-effects, hypoglycaemia, documentation, cardio-
vascular effects, combination with insulin and use in special population), patients’ 
acceptability (formulation, dose frequency, weight change) and cost. The average 
weights assigned by panel members for efficacy, safety, patients acceptability and 
cost were 23.89%, 43.89%, 20.33%, and 11.89%, respectively. Gliclazide scored consist-
ently high for both efficacy and safety attributes resulting in TUS of 68.5 and 67.4 for 
gliclazide modified release and gliclazide respectively. Safety concerns lowered the 
TUS for glibenclamide to 56.8. Potential direct savings on drug costs was estimated 
to be over RM3 million per year resulting from reduction in glibenclamide utilization 
from 30% to 5%. ConClusions: MedSS successfully organized the attributes and 
utilities of the drugs compared, distinguishing gliclazide as the superior alternative. 
Providing patients with access to drugs of higher TUS could additionally results in 
indirect savings beyond drug costs. Moreover, benefits of clinicians’ involvement are 
twofold: better acceptance of any changes to the formulary list leads to improved 
prescribing pattern that could also positively impact drug expenditures.
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objeCtives: Half of the world’s population is estimated to be infected with 
Helicobacter pylori (H. pylori), a bacterium shown to be linked with a series of 
gastrointestinal diseases. A growing number of systematic reviews have been pub-
lished comparing the effectiveness of treatment regimens in the eradication of 
H. pylori, but have not reached a consistent conclusion. This study provides an 
overview of systematic reviews of pharmacological therapies for the eradication of 
H. pylori. Methods: We searched major electronic databases from 2002 to 2013. 
Studies were considered eligible if they included RCTs comparing different phar-
macological regimens for treatment of patients diagnosed as H. pylori infected 
and pooled the eradication rates in a meta-analysis. A modified version of ‘A 
Measurement Tool to Assess Systematic Reviews’ (AMSTAR) was used to assess the 
methodological quality. Where appropriate, network meta-analysis of proton pump 
inhibitors (PPI) or antibiotics within treatment regimens was conducted. Results: 
24 systematic reviews with pairwise meta-analysis were included. In triple therapy, 
more recently published studies tend to suggest new generation PPIs (esomeprazole 
and rabeprazole) achieve greater eradication rates than the older generation (ome-
prazole, pantoprazole and lansoprazole); furthermore, moxifloxacin and levofloxa-
cin were both associated with greater effectiveness and lower risk of adverse events 
than clarithromycin. When comparing triple and bismuth based therapy, the relative 
effectiveness appeared to be dependent on the antibiotics within the triple therapy. 
A network meta-analysis based on the data from the systematic reviews was able 
to provide ranking of relative effectiveness of individual PPIs. ConClusions: 
Current clinical guidelines do not distinguish between individual PPIs or antibiot-
ics. However, our analysis of the recent evidence suggests that the new generation 
of PPIs and use of moxifloxacin or levofloxacin in triple therapy were associated 
with greater effectiveness of H. pylori eradication.
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objeCtives: TC-325 is a novel endoscopic hemostatic powder, recently adapted for 
gastrointestinal (GI) bleeding. However, data on its use, effectiveness, safety, and 
indications are very limited. To describe a single-centre experience with TC-325 use 
in a variety of pathologies from the upper and lower GI tract focusing on hemostasis, 
residency time of the powder on the lesion, and safety. Methods: Retrospective 
chart review of all patients identified through a dedicated endoscopic database as 
having received TC-325 therapy between July 2011 and July 2013. Primary endpoints 
include initial hemostasis and early rebleeding (≤ 72 hours). Data on residency 
time of the product, delayed rebleeding, transfusion and intensive care require-
ments, need for angioembolization, radiation therapy, and emergent surgery, rou-
tine second-look endoscopy and complications associated with TC-325 were also 
recorded. Results: Overall there were 67 treatments using TC-325 in 60 patients. 
Their mean age was 68.1 years ± 13.5, with a male predominance of 65%. There were 
21 treatments for non-malignant non variceal upper GI bleeding, 19 for malignant 
